Innovative Targeted and Immune-Mediated Cancer Therapies

Pipeline

Developing first-in-class oral drug therapeutics with broad potential benefit for cancer patients

Learn more

Science

Thoughtful exploration of new and validated pathways to discover and develop novel therapeutics

Learn more

News

June 30, 2025
Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China

June 11, 2025
Tempest Announces $4.6 Million Registered Direct Offering of Common Stock

June 5, 2025
Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC

Events

Tuesday, December 3RD, 2024 at 9:00 AM Eastern
Piper Sandler 36th Annual Healthcare Conference
Listen: Webcast

Thursday, June 20TH, 2024 at 8:30 AM Eastern
Amezalpat (TPST-1120) Global Randomized Phase 1b/2 Combination Study Update Call
Listen: Webcast
Download: Presentation [pdf]

Wednesday, October 11TH, 2023 at 8:30 AM Eastern
TPST-1120 Global Randomized Phase 1b/2 Combination Study Data Call
Listen: Webcast
Download: Presentation [pdf]